These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 17970221)

  • 1. Programs to facilitate tuberculosis drug discovery: the tuberculosis antimicrobial acquisition and coordinating facility.
    Goldman RC; Laughon BE; Reynolds RC; Secrist JA; Maddry JA; Guié MA; Poffenberger AC; Kwong CA; Ananthan S
    Infect Disord Drug Targets; 2007 Jun; 7(2):92-104. PubMed ID: 17970221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv.
    Ananthan S; Faaleolea ER; Goldman RC; Hobrath JV; Kwong CD; Laughon BE; Maddry JA; Mehta A; Rasmussen L; Reynolds RC; Secrist JA; Shindo N; Showe DN; Sosa MI; Suling WJ; White EL
    Tuberculosis (Edinb); 2009 Sep; 89(5):334-53. PubMed ID: 19758845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
    Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
    Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro evaluation of tetrazoles as a novel class of Antimycobacterium tuberculosis agents.
    Mohite PB; Bhaskar VH
    Adv Pharm Bull; 2012; 2(1):31-6. PubMed ID: 24312768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis.
    Franzblau SG; DeGroote MA; Cho SH; Andries K; Nuermberger E; Orme IM; Mdluli K; Angulo-Barturen I; Dick T; Dartois V; Lenaerts AJ
    Tuberculosis (Edinb); 2012 Nov; 92(6):453-88. PubMed ID: 22940006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physicochemical, pharmacokinetic, efficacy and toxicity profiling of a potential nitrofuranyl methyl piperazine derivative IIIM-MCD-211 for oral tuberculosis therapy via in-silico-in-vitro-in-vivo approach.
    Magotra A; Sharma A; Singh S; Ojha PK; Kumar S; Bokolia N; Wazir P; Sharma S; Khan IA; Singh PP; Vishwakarma RA; Singh G; Nandi U
    Pulm Pharmacol Ther; 2018 Feb; 48():151-160. PubMed ID: 29174840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antituberculosis activity of the molecular libraries screening center network library.
    Maddry JA; Ananthan S; Goldman RC; Hobrath JV; Kwong CD; Maddox C; Rasmussen L; Reynolds RC; Secrist JA; Sosa MI; White EL; Zhang W
    Tuberculosis (Edinb); 2009 Sep; 89(5):354-63. PubMed ID: 19783214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tuberculosis activity of some N-pentopyranosylamines.
    Moczulska A
    Acta Pol Pharm; 2004; 61(4):259-62. PubMed ID: 15575591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of shikimate kinase inhibitors among anti-Mycobacterium tuberculosis compounds by LC-MS.
    Simithy J; Reeve N; Hobrath JV; Reynolds RC; Calderón AI
    Tuberculosis (Edinb); 2014 Mar; 94(2):152-8. PubMed ID: 24429106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The resumption of consumption -- a review on tuberculosis.
    Ducati RG; Ruffino-Netto A; Basso LA; Santos DS
    Mem Inst Oswaldo Cruz; 2006 Nov; 101(7):697-714. PubMed ID: 17160276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational medicinal chemistry for rational drug design: Identification of novel chemical structures with potential anti-tuberculosis activity.
    Koseki Y; Aoki S
    Curr Top Med Chem; 2014; 14(1):176-88. PubMed ID: 24236720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward an Evidence-Based Nonclinical Road Map for Evaluating the Efficacy of New Tuberculosis (TB) Drug Regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious Diseases In Vivo Pharmacology Workshop for TB Drug Development.
    Nuermberger E; Sizemore C; Romero K; Hanna D
    Antimicrob Agents Chemother; 2016 Jan; 60(3):1177-82. PubMed ID: 26824941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The future for early-stage tuberculosis drug discovery.
    Zuniga ES; Early J; Parish T
    Future Microbiol; 2015; 10(2):217-29. PubMed ID: 25689534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and validation of new antitubercular compounds as potential drug leads and probes.
    Goldman RC; Laughon BE
    Tuberculosis (Edinb); 2009 Sep; 89(5):331-3. PubMed ID: 19716767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents.
    Keri RS; Sasidhar BS; Nagaraja BM; Santos MA
    Eur J Med Chem; 2015 Jul; 100():257-69. PubMed ID: 26112067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.